Phase III trial of dronedarone/ranolazine in patients with atrial fibrillation

Trial Profile

Phase III trial of dronedarone/ranolazine in patients with atrial fibrillation

Planning
Phase of Trial: Phase III

Latest Information Update: 26 May 2014

At a glance

  • Drugs Dronedarone/ranolazine (Primary)
  • Indications Atrial fibrillation
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 26 May 2014 New trial record
    • 10 May 2014 Gilead is planning this phase III trial assessing a fixed-dose combination (FDC) of ranolazine and low-dose dronedarone for paroxysmal or persistent (non-permanent) atrial fibrillation, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top